XML 59 R49.htm IDEA: XBRL DOCUMENT v3.7.0.1
Collaborative Agreements (Details)
1 Months Ended 3 Months Ended
Aug. 07, 2015
USD ($)
product
Feb. 28, 2017
USD ($)
patient
Apr. 30, 2015
USD ($)
Sep. 30, 2013
USD ($)
Mar. 31, 2017
USD ($)
Mar. 31, 2016
USD ($)
Roche [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Full payment   $ 8,500,000        
Clawback portion   $ 2,100,000        
Number of patients threshold | patient   90        
Collaborative Arrangement, Product [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Upfront payment received       $ 10,000,000    
Collaborative Arrangement, Product [Member] | INO-3112 [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Revenue recognized $ 15,000,000          
Collaborative Arrangement, Product [Member] | License To Research Collaboration Products [Member] | Nonsoftware License Arrangement [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Deferred revenue, additions 12,500,000          
Collaborative Arrangement, Product [Member] | INO 5150 [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Revenue recognized       8,400,000    
Collaborative Arrangement, Product [Member] | Option Right [Member] | Nonsoftware License Arrangement [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Deferred revenue, additions       1,500,000    
Collaborative Arrangement, Product [Member] | Joint Steering Committee Obligation [Member] | Nonsoftware License Arrangement [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Deferred revenue, additions       $ 155,000    
Collaborative Arrangement, Product [Member] | MedImmune [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Upfront payment received 27,500,000          
Anticipated development and regulatory event based payment receivable milestones $ 700,000,000          
Number of additional products to be developed | product 2          
Revenue under collaborative research and development arrangements         $ 306,000 $ 390,000
Deferred revenue         13,800,000  
Accounts receivable         1,100,000  
Collaborative Arrangement, Product [Member] | Hoffman-La Roche [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Deferred revenue         2,100,000  
Accounts receivable         0  
Previously deferred revenue recognized         4,000,000 1,400,000
Collaborative Arrangement, Product [Member] | Defense Advanced Research Projects Agency (DARPA) [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Deferred revenue         1,200,000  
Accounts receivable         8,500,000  
Previously deferred revenue recognized         $ 5,000,000 $ 4,600,000
Term     2 years      
Base award     $ 19,600,000      
Option award     24,600,000      
Second option award     $ 11,100,000